 |
66 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
313 Trials |  |
11771 News |  |
| «12...209210211212213214215216217218219220221» |
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 9, 2015
P1, N=39, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jan 2017 --> Oct 2016
- | Zydelig (idelalisib) / Gilead
New P2 trial: Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis (clinicaltrials.gov) - Oct 29, 2015
P2, N=18, Not yet recruiting, Sponsor: John Mark Sloan
- | Zydelig (idelalisib) / Gilead
Enrollment open, Trial initiation date: Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenstr (clinicaltrials.gov) - Oct 28, 2015
P2, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jan 2017 --> Oct 2016 Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Oct 2015
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date: BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy (clinicaltrials.gov) - Oct 22, 2015
P2, N=41, Recruiting, Sponsor: Prince of Songkla University
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Oct 2015 Trial primary completion date: Dec 2014 --> Dec 2016
- || Piqray (alpelisib) / Novartis
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Oct 22, 2015
P1, N=55, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Jul 2015 --> Dec 2015
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed: Neoadjuvant BKM120 in High-risk Prostate Cancer (clinicaltrials.gov) - Oct 5, 2015
P2, N=24, Active, not recruiting, Sponsor: Charles Ryan
Trial primary completion date: Jul 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer (clinicaltrials.gov) - Sep 24, 2015
P2, N=50, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed | N=220 --> 50 | Trial primary completion date: Feb 2016 --> Feb 2015
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment status: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Aug 25, 2015
P2b, N=58, Recruiting, Sponsor: Medical Research Council
Recruiting --> Completed | N=220 --> 50 | Trial primary completion date: Feb 2016 --> Feb 2015 Enrolling by invitation --> Recruiting
- || buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR (clinicaltrials.gov) - Aug 19, 2015
P1, N=58, Recruiting, Sponsor: National Cancer Centre, Singapore
Enrolling by invitation --> Recruiting Trial primary completion date: Dec 2013 --> Dec 2016
- pictilisib (GDC-0941) / Roche
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Aug 19, 2015
P1/2, N=11, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Trial primary completion date: Dec 2013 --> Dec 2016 N=120 --> 11 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Dec 2014; company stopped production of study drug due to excessive toxicities, lack of efficacy
- Piqray (alpelisib) / Novartis
Trial primary completion date, Combination therapy, Metastases: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 13, 2015
P1, N=30, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
N=120 --> 11 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Dec 2014; company stopped production of study drug due to excessive toxicities, lack of efficacy Trial primary completion date: Oct 2015 --> Oct 2017
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer (clinicaltrials.gov) - Jul 10, 2015
P1, N=31, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Jun 2015 --> Sep 2015
- |||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, taselisib (GDC-0032) / Roche
Enrollment open, Combination therapy, Metastases: Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 10, 2015
P1/2, N=74, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial primary completion date: Jun 2015 --> Sep 2015 Not yet recruiting --> Recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Trial primary completion date: Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 25, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Biomarker, Trial primary completion date, Combination therapy, Metastases: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jun 23, 2015
P1/2, N=30, Recruiting, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Jun 2015 --> Jun 2016
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment status: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Jun 18, 2015
P2b, N=58, Enrolling by invitation, Sponsor: Medical Research Council
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Enrolling by invitation
- || pimasertib (AS703026) / Day One Biopharma
Trial primary completion date, Combination therapy, Metastases: EMR 200066-006: Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 11, 2015
P1, N=146, Completed, Sponsor: EMD Serono
Recruiting --> Enrolling by invitation Trial primary completion date: Apr 2014 --> Apr 2015
- ||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, taselisib (GDC-0032) / Roche
New P1/2 trial, Combination therapy, Metastases: Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - May 29, 2015
P1/2, N=74, Not yet recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- || pimasertib (AS703026) / Day One Biopharma
Enrollment change, Combination therapy, Metastases: EMR 200066-006: Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 14, 2015
P1, N=146, Completed, Sponsor: EMD Serono
Trial primary completion date: Apr 2014 --> Apr 2015 N=259 --> 146
- | Zydelig (idelalisib) / Gilead
New P2 trial: Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenstr (clinicaltrials.gov) - May 8, 2015
P2, N=30, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Combination therapy, Metastases: PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 6, 2015
P1, N=39, Active, not recruiting, Sponsor: City of Hope Medical Center
N=259 --> 146 Recruiting --> Active, not recruiting
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
New P2b trial: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Apr 30, 2015
P2b, N=58, Recruiting, Sponsor: Medical Research Council
- ||||| buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial, Combination therapy, Metastases: PIKTAM: Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer (clinicaltrials.gov) - Apr 2, 2015
P2, N=99, Recruiting, Sponsor: University Hospital, Essen
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Metastases: Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer (clinicaltrials.gov) - Mar 25, 2015
P1, N=40, Active, not recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Ibrance (palbociclib) / Pfizer, taselisib (GDC-0032) / Roche, pictilisib (GDC-0941) / Roche
New P1 trial, Combination therapy: PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (clinicaltrials.gov) - Mar 17, 2015
P1, N=93, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
- || Aliqopa (copanlisib) / Bayer
Trial primary completion date: CHRONOS-1: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Feb 19, 2015
P2, N=180, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> May 2016
- Aliqopa (copanlisib) / Bayer
Trial primary completion date, Combination therapy, Metastases: Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer (clinicaltrials.gov) - Feb 3, 2015
P1, N=50, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Feb 2016 --> May 2016 Trial primary completion date: Dec 2014 --> Jun 2015
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment change, Combination therapy, Metastases: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer (clinicaltrials.gov) - Jan 15, 2015
P1, N=31, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2014 --> Jun 2015 N=22 --> 31
- || Piqray (alpelisib) / Novartis
Enrollment closed, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Jan 7, 2015
P1, N=55, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=22 --> 31 Recruiting --> Active, not recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Combination therapy, Surgery, Metastases: PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic (clinicaltrials.gov) - Dec 24, 2014
P1, N=38, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Piqray (alpelisib) / Novartis, sotrastaurin (AEB071) / Novartis
Enrollment open, Combination therapy, Metastases: Trial of AEB071 in Combination With BYL719 in Patients With Melanoma (clinicaltrials.gov) - Dec 19, 2014
P1, N=50, Recruiting, Sponsor: Gary Schwartz
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed: NCI-2012-01514: Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer (clinicaltrials.gov) - Dec 17, 2014
P2, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Trial primary completion date, Metastases: Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium (clinicaltrials.gov) - Dec 12, 2014
P2, N=35, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Completed --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Mar 2016
- ||| fimepinostat (CUDC-907) / Curis
New P1 trial, Metastases: Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors (clinicaltrials.gov) - Dec 5, 2014
P1, N=60, Recruiting, Sponsor: Curis, Inc.
- || Aliqopa (copanlisib) / Bayer
Trial primary completion date: CHRONOS-1: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Oct 30, 2014
P2, N=180, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: May 2015 --> Feb 2016
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date: Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=20, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: May 2015 --> Feb 2016 Trial primary completion date: Dec 2014 --> Sep 2015
- Piqray (alpelisib) / Novartis, sotrastaurin (AEB071) / Novartis
New P1 trial, Combination therapy, Metastases: Trial of AEB071 in Combination With BYL719 in Patients With Melanoma (clinicaltrials.gov) - Oct 23, 2014
P1, N=50, Not yet recruiting, Sponsor: Columbia University
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Trial primary completion date, Metastases: SOLTI-1103: A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 15, 2014
P2, N=50, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
Trial primary completion date: Dec 2014 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Nov 2014
- Aliqopa (copanlisib) / Bayer
Trial primary completion date, Combination therapy, Metastases: Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=50, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Nov 2014 Trial primary completion date: Jul 2014 --> Dec 2014
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer (clinicaltrials.gov) - Sep 22, 2014
P1, N=22, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jul 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jun 2015
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date: Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 15, 2014
P=N/A, N=18, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Sep 2014 --> Dec 2014
- | Piqray (alpelisib) / Novartis
Trial completion, Enrollment change, Combination therapy, Metastases: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Sep 15, 2014
P1, N=18, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2014 --> Dec 2014 Recruiting --> Completed | N=41 --> 18
- ||| refametinib (BAY86-9766) / Bayer, Aliqopa (copanlisib) / Bayer
Trial completion, Enrollment change, Trial primary completion date, Metastases: Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer (clinicaltrials.gov) - Sep 4, 2014
P1, N=68, Completed, Sponsor: Bayer
Recruiting --> Completed | N=41 --> 18 Active, not recruiting --> Completed | N=92 --> 68 | Trial primary completion date: Jun 2014 --> Feb 2014
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date: Neoadjuvant BKM120 in High-risk Prostate Cancer (clinicaltrials.gov) - Aug 18, 2014
P2, N=24, Recruiting, Sponsor: Charles Ryan
Active, not recruiting --> Completed | N=92 --> 68 | Trial primary completion date: Jun 2014 --> Feb 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Metastases: Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer (clinicaltrials.gov) - Jul 23, 2014
P1, N=40, Recruiting, Sponsor: University of California, Davis
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- | buparlisib (AN2025) / Novartis, Adlai Nortye
New P1 trial, Metastases: Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer (clinicaltrials.gov) - Jul 18, 2014
P1, N=40, Not yet recruiting, Sponsor: University of California, Davis
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Monotherapy, Metastases: PIK-ORL: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (clinicaltrials.gov) - Jul 12, 2014
P2, N=70, Recruiting, Sponsor: Centre Leon Berard
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Mar 2016
- ||| pimasertib (AS703026) / Day One Biopharma
Trial completion, Combination therapy, Metastases: EMR 200066-006: Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 10, 2014
P1, N=259, Completed, Sponsor: EMD Serono
Trial primary completion date: Sep 2014 --> Mar 2016 Active, not recruiting --> Completed
- ||| pimasertib (AS703026) / Day One Biopharma
Trial completion, Enrollment change, Combination therapy, Metastases: EMR 200066-006: Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 7, 2014
P1, N=170, Active, not recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed N=90 --> 170 | Active, not recruiting --> Completed
- Piqray (alpelisib) / Novartis
Trial primary completion date, Combination therapy, Metastases: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jun 19, 2014
P1, N=30, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
N=90 --> 170 | Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Oct 2015